Clinical Trial Update: A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma [Phase 3]

View source ↗

Summary

A Phase 3 study of the anti-PD-1 antibody PDR001 in combination with dabrafenib and trametinib in advanced melanoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• PDR001
• Trametinib (trametinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma | Phase 3 | Status: TERMINATED | Results posted: 2023-07-24